Dr. John Cush RheumNow
1 year 1 month ago
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.
Dr. John Cush RheumNow
1 year 1 month ago
Does Abatacept Buy You Time Off RA?
Dr. David Liew reports on abstract OP0325 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/t8NLvPjcju https://t.co/bloTKQ87rv
Dr. John Cush RheumNow
1 year 1 month ago
Not All About B Cells: Myeloid Related Inflammation in Lupus Pathogenesis
Dr. Andrea Fava shares his perspectives from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/8Lh02c3sy4 https://t.co/XX7wKovD9u
Dr. John Cush RheumNow
1 year 1 month ago
Social Determinants of Health in SLE
Dr. Mrinalini Dey interviews Dr. Elena Nikiphorou about the topic of social determinants of health in systemic lupus erythematosus, and data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/gSFIV8uIuE https://t.co/VpqzVRSwh9
Dr. John Cush RheumNow
1 year 1 month ago
Add-on certolizumab in pregnant women with APS
Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). https://t.co/qnnkFlhtiS
Dr. John Cush RheumNow
1 year 1 month ago
Secukinumab & Uveitis = Unclear? Post hoc study of 11 SEC RCTs finds lower uveitis risk in AxSpA (N 1980; SEC 150 1.29/100PYs vs 1.72/100PY in PBO), but not in PsA (N 2453; SEC 300 0.71/100PY vs zero w/ placebo) https://t.co/Gv9HheBU7l https://t.co/SlnrLRwmmn
Dr. John Cush RheumNow
1 year 1 month ago
Predicting Psoriatic Arthritis in Psoriasis: How Close Are We?
Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies https://t.co/RLz1FoQxvc
Dr. John Cush RheumNow
1 year 1 month ago
Nurse-Led Treat-to-Target Clinics
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez
Dr. John Cush RheumNow
1 year 1 month ago
How to properly use steroids in early RA
Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. https://t.co/FakKxRot0p
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treatment and their lives better?
Dr. John Cush RheumNow
1 year 1 month ago
Methotrexate and Leflunomide combination in RA/PsA: Is it safe? Save
I asked the EULAR Twitter community about the combination of Methotrexate (MTX) and Leflunomide (LEF). Opinions are split, with 50% prescribing it often and 50% concerned about side effects. In my practice, https://t.co/SZjLaEH1h2
